PMID- 38396308
OWN - NLM
STAT- MEDLINE
DCOM- 20240516
LR  - 20240516
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 80
IP  - 6
DP  - 2024 Jun
TI  - Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): 
      which one may be the first option in group A COPD patients?
PG  - 847-853
LID - 10.1007/s00228-024-03637-1 [doi]
AB  - INTRODUCTION: Long-acting muscarinic antagonists (LAMA) or beta-2 agonists (LABA) 
      have been recommended for symptom control in group A COPD patients as a 
      first-line bronchodilator treatment in GOLD guidelines. However, there is no 
      mention of priority/superiority between the two treatment options. We aimed to 
      compare the effectiveness of these treatments in this group. METHODS: The study 
      cohort was formed of all subjects from six pulmonology clinics with an initial 
      diagnosis of COPD who were new users of a LAMA or LABA from January 2020 to 
      December 2021. Seventy-six group A COPD patients, in whom LABA or LAMA therapy 
      had been started in the last 1 month as a first-line treatment, were included in 
      our study. Participants were evaluated with spirometry, COPD Assessment Test 
      (CAT), mMRC scale, and St. George Respiratory Questionnaire (SGRQ) for three 
      times (baseline, 6-12(th) months). RESULTS: There were 76 group A COPD patients 
      with LAMA (67.1%) and LABA (32.9%). The number of patients who improved in CAT 
      score at the end of the first year was significantly higher in patients using 
      LAMA than those using LABA (p = 0.022); the improvement at minimum clinically 
      important difference (MCID) in CAT score of LAMA group at 1(st) year was also 
      significant (p = 0.044). SGRQ total and impact scores were found to be 
      statistically lower at 1(st) year compared to baseline in patients using LAMA 
      (p = 0.010 and 0.006, respectively). Significant improvement was detected in CAT 
      and SGRQ scores at the 6(th) month visit in the LAMA group having emphysema 
      (p = 0.032 and 0.002, respectively). CONCLUSION: According to significant 
      improvements in CAT and SGRQ score, LAMA may be preferred over LABA as a 
      bronchodilator agent in group A COPD patients, especially in emphysema-dominant 
      phenotype.
CI  - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Turan, Onur
AU  - Turan O
AUID- ORCID: 0000-0001-6320-0470
AD  - Chest Diseases Department, Izmir Katip Celebi University, Izmir, Turkey. 
      onurtura@yahoo.com.
FAU - Ogan, Nalan
AU  - Ogan N
AUID- ORCID: 0000-0001-5232-3803
AD  - Chest Diseases Department, Ufuk University, Ankara, Turkey.
FAU - Bozkus, Fulsen
AU  - Bozkus F
AUID- ORCID: 0000-0002-6498-4390
AD  - Chest Diseases Department, Kahramanmaras Sutcu Imam University, Kahramanmaras, 
      Turkey.
FAU - Sarioglu, Nurhan
AU  - Sarioglu N
AUID- ORCID: 0000-0002-5180-9649
AD  - Chest Diseases Department, Balikesir University, Balikesir, Turkey.
FAU - Turan, Pakize Ayse
AU  - Turan PA
AUID- ORCID: 0000-0002-9325-4303
AD  - Chest Diseases Department, Menemen State Hospital, Izmir, Turkey.
FAU - Satici, Celal
AU  - Satici C
AUID- ORCID: 0000-0002-5457-9551
AD  - Chest Diseases Department, Istanbul Gaziosmanpasa Research and Training Hospital 
      University, Istanbul, Turkey.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20240223
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
SB  - IM
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive/drug therapy
MH  - Male
MH  - Female
MH  - *Adrenergic beta-2 Receptor Agonists/therapeutic use/administration & dosage
MH  - *Muscarinic Antagonists/administration & dosage/therapeutic use
MH  - Aged
MH  - Middle Aged
MH  - Bronchodilator Agents/therapeutic use/administration & dosage
MH  - Treatment Outcome
MH  - Spirometry
MH  - Muscarinic Agonists/therapeutic use/administration & dosage
MH  - Delayed-Action Preparations
OTO - NOTNLM
OT  - COPD
OT  - Group A
OT  - Long-acting beta-2 agonists (LABA)
OT  - Long-acting muscarinic antagonists (LAMA)
OT  - Treatment
EDAT- 2024/02/24 11:45
MHDA- 2024/05/16 12:43
CRDT- 2024/02/24 00:07
PHST- 2023/10/09 00:00 [received]
PHST- 2024/01/23 00:00 [accepted]
PHST- 2024/05/16 12:43 [medline]
PHST- 2024/02/24 11:45 [pubmed]
PHST- 2024/02/24 00:07 [entrez]
AID - 10.1007/s00228-024-03637-1 [pii]
AID - 10.1007/s00228-024-03637-1 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2024 Jun;80(6):847-853. doi: 10.1007/s00228-024-03637-1. 
      Epub 2024 Feb 23.